To rapidly respond to invading microorganisms, humans call on their innate immune system. This occurs by microbe-detecting receptors, such as CD14, that activate immune cells to eliminate the pathogens. Here, we link the lipopolysaccharide receptor CD14 with Alzheimer`s disease, a severe neurodegenerative disease resulting in dementia. We demonstrate that this key innate immunity receptor interacts with fibrils of Alzheimer amyloid peptide. Neutralization with antibodies against CD14 and genetic deficiency for this receptor significantly reduced amyloid peptide induced microglial activation and microglial toxicity. The observation of strongly enhanced microglial expression of the LPS receptor in brains of animal models of Alzheimer's disease indicates a clinical relevance of these findings. These data suggest that CD14 may significantly contribute to the overall neuroinflammatory response to amyloid peptide, highlighting the possibility that the enormous progress currently being made in the field of innate immunity could be extended to research on Alzheimer's disease.
lzheimer's disease (AD), the most common cause of progressive intellectual decline, is characterized by numerous cerebral senile plaques that are composed of Aβ (1) . The mechanisms of neuronal damage are uncertain. Several lines of evidence indicate that such cerebral Aβ deposits elicit a chronic, disseminated inflammatory host response that, over years and decades, leads to neurodegeneration (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . These include the strong accumulation of microglia around plaques (2) (3) (4) , the pronounced microglial activation by Aβ to release neurotoxic mediators (5-7), or the protective effects of anti-inflammatory drugs in large epidemiological studies (8, 9) . Also the efficacy of vaccination of APP-overexpressing mice against Aβ (10) (11) (12) , which is thought to enhance microglial phagocytosis of Aβ (12) , argues for a crucial role of inflammation in AD.
Currently, the innate immune research is experiencing an impressive revival, as pattern recognition receptors recognizing highly conserved surface structures common to many microorganisms have been detected (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Those receptors are crucial for rapid killing of invading pathogens. The glycosylphosphatidyl-inositol-anchored lipopolysaccharide (LPS) receptor CD14 mediates cellular activation by components of microorganisms such as LPS or other highly hydrophobic and aggregated structures (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Because Aβ forms similar highly hydrophobic aggregates in AD plaques, we investigated whether CD14 could mediate Aβ-induced neuroinflammation and if it is associated with pathological features of disease.
MATERIALS AND METHODS

Antibodies
The following mAbs were used: rat anti-mouse CD14 (rmC5-3, PharMingen, San Diego, CA), rat anti-mouse CD14 (4C1, purified and FITC-labeled, 21), mouse anti human CD14 (3C10, R. Landmann), mouse anti-human Aβ (W02, Center of Molecular Biology, Heidelberg, Germany), rat anti-mouse CD45 (APC-labeled, PharMingen), and rat anti-mouse Mac-1 (PE-labeled, PharMingen). These polyclonal antibodies used were goat anti-mouse sTNF-αRII (R&D Systems) and rabbit anti-mouse calcium binding adaptor molecule 1 (iba1, Y. Imai, Kodaira, Japan).
Preparation and characterization of fibrillar peptides
Fibrillar Aβ was obtained by dissolving synthetic human Aβ 1-42 (Department of Medical Chemistry, Albert Szent Gyorgyi University, Szeged, Hungary) in deionized sterile water (1 mg/ml), and incubating it for 7 days at 37°C as described previously (5) . Fibrillogenesis of nonfibrillar peptides was prevented by diluting the stock solution to a final concentration of 62.5 µg/ml and immediately freezing. The fibrillar and nonfibrillar conformation of peptides was confirmed by using electron microscopy (5). Mass spectroscopy of Aβ showed the absence of contamination. Endotoxin concentrations of fibrillar, nonfibrillar, and scrambled Aβ species were below detection limit (0.01 EU/ml) in the Limulus Amoebocyte assay (Whittaker Bioproducts, Walkersville, MD). Polymyxin B did not block Aβ-induced cellular activation, which further excludes effects of LPS contamination.
A
Immunoprecipitation and Western blot experiments
Aβ fibrils were incubated with murine recombinant sCD14 (46 kDa, prepared by R. Landmann, Basel, Switzerland) for 12 h at 4°C and immunoprecipitated with anti-Aβ Ab (W02, 3 µg/ml) immobilized to Sepharose-G. Protein separation was performed with a 7% Tris-glycine gel followed by full wet transfer to a nitrocellulose membrane for CD14 detection (23) . Membranes were incubated with anti-CD14 mAb (rmC5-3, 1 µg/ml) and HRP-conjugated anti-rat IgG (1:10.000) as secondary antibody. The blots were developed by ECL (Amersham, Little Chalfont, UK).
Surface plasmon resonance spectroscopy
The binding between Aβ and CD14 was investigated by using real-time surface plasmon resonance spectroscopy (BIACORE-Upgrade System, BIACORE, Freiburg, Germany). Measurements were performed at 37°C in 10 mM HEPES (pH 7.4), 150 mM NaCl, and 0.005% surfactant P20 at a flow rate of 10 µl/min. Aβ was coupled to a CM5 sensor chip by standard NHS/EDC chemistry in amounts that yielded 750 to 1500 response units. Human recombinant sCD14 (R&D Systems) was injected for 300 s then eluted for 200 to 300 s in HBS buffer (concentration range from 10 to 100µg/ml). The sensor chip surface was regenerated by injecting 30 µl 20 mM HCl to remove residual sCD14 from immobilized Aβ. The association and dissociation constants were calculated by using the BIA-Evaluation program (BIACORE). The .
Aβ-stimulation of microglia and effects of blocking anti-CD14 mAbs and genetic deficiency for CD14
Primary murine microglia (Balb/c), CD14-deficient microglia, and respective wild-type controls (C57BL6) were prepared as described previously (5) . The purity of the culture was confirmed by cellular expression of the monocytic marker Mac-1 and by low expression of the leukocyte common antigen (CD45; ref 24) . Cells were stimulated with fibrillar, nonfibrillar, or scrambled Aβ. As positive control, LPS, derived from E. coli, (Sigma, in the CD14 neutralization experiments) or from S. abortus equi (Sigma, in experiments with genetically deficient microglia), was used. Murine IFN-γ (Sigma) was administered as a costimulatory factor as described previously (5, 6) . Inflammatory cytokines were quantified in the supernatant collected after 6 and 24 h by ELISA (R&D Systems). Nitrite was measured in the supernatant after 24 and 48 h by the Grieß assay (5). The effect of blocking anti-mouse CD14 mAb (4C1; ref 21) or isotype control mAb or CD14 deficiency was investigated. Treatment with peptides or antibodies did not affect cell viability as measured by LDH and MTT assays (Promega, Mannheim, Germany). In similar experiments, human peripheral blood monocytes were incubated with 50 µg/ml Aβ for 15 h with or without the neutralizing anti-human CD14 mAb (3C10).
Transfection, culture and stimulation of CHO cells
CHO-K1 cells (DSM ACC 110) were transfected with human pCEP4-CD14 or an empty control vector. Cells (1×10 6 /well) in 6-well plates were stimulated with LPS from S. enterica serovar Friedenau, provided by H. Brade (Borstel, Germany) or Aβ for 1 h in Ham's F-12 containing 2% human serum and antibiotics.
Preparation of nuclear extracts and electrophoretic mobility shift assay
The preparation of nuclear extracts and electrophoretic mobility shift assay (EMSA) was performed as described elsewhere (25) . Briefly, we used 7.5 fmol γ-[
32 P]dATP-labeled oligonucleotides containing the NFκB binding sequence and 4 µg of crude nuclear extract in the DNA binding reaction. Samples were incubated for 20 min at 4°C and were separated by electrophoresis on 4% polyacrylamide gels. Gels were analyzed by using a PhosphorImager (Molecular Dynamics, Krefeld, Germany).
Neurotoxicity of Aβ-activated CD14
−/− and CD14 +/+ microglia Primary murine hippocampal neurons were seeded in 24-well plates (8x10 4 cells per well in neuron culture medium: BME supplemented with 2% B-27 and 1% FCS) for 7 days. Supernatant from Aβ-activated microglia (24 h stimulation with 50 µg/ml fibrillar Aβ1−42 as described above) 1:2 diluted with neuron culture medium was administered to the neurons. After 24 h, neuronal death was detected by MTT assay.
In situ hybridization histochemistry and dual labeling
Coronal sections (20 µm) of postfixed (10% sucrose/4% paraformaldehyde-borax buffer) brains of APP23 mice, overexpressing human APP751 with the Swedish double mutation under the control of a murine Thy-1 promotor (26) and age-matched control mice were processed for immunohistochemistry, prehybridization, hybridization, and posthybridization as described previously (27) . The presence of CD14 transcript was detected by the agglomeration of silver grains in perikarya. Immunohistochemical staining for iba1 antibody was combined with the in situ hybridization protocol to determine whether microglial cells express CD14 transcript in the mouse brain.
RESULTS
CD14 interacts with Aβ fibrils
To determine whether CD14 binds Alzheimer Aβ, we used different approaches. First, fibrillar human Aβ1-42 was coincubated with recombinant soluble murine CD14. Complexes were immunoprecipitated and assessed by Western blot. The results demonstrate binding of Aβ fibrils to CD14 (Fig. 1) . Omission of Aβ or the use of an isotype control antibody prevented the precipitation of CD14 (Fig. 1) . Coincubation with the control peptide, TNF-α receptor-II instead of CD14 did not result in a coimmunoprecipitation as indicated by the absence of a corresponding band (not shown).
To further study binding between CD14 and Aβ, we used real-time surface plasmon resonance spectroscopy analysis. The observed changes induced in the relative diffraction were recorded as a function of time. The kinetic constants of association (150-400 s) and dissociation (400-600 s) were calculated as mean values from the slopes of the curves. These studies demonstrate a binding between CD14 and Aβ1-42. The interaction between CD14 and fibrillar Aβ1-42 (K D [M]: 1.1±0.1×10 −7 ) was 20-fold higher than the one for the interaction between CD14 and nonfibrillar Aβ1-42, indicating the importance of the fibrillar structure of the peptide in the binding to CD14 (Table 1) . No binding between CD14 and nonfibrillar Aβ1-40, a much weaker amyloidogenic peptide, was detected. Hence, these findings show an interaction between CD14 and Aβ1-42 in dependence on its fibrillar conformation.
Antibodies against CD14 and genetic deficiency for CD14 strongly reduce Aβ-induced microglial activation and neurotoxicity
To determine the functional implications of the binding of Aβ to CD14, we investigated whether their interaction results in activation of cultured primary murine microglial cells. FACScan analysis revealed that 40-50% of the microglia were CD14 positive. The blocking anti-CD14 mAb, 4C1 (21) significantly reduced the strong Aβ/IFN-γ-induced release of nitrite, the stable metabolite of nitric oxide ( Fig. 2A) , and the cytokines IL-6 (Fig. 2B) or TNF-α (not shown). An Aβ-triggered release of inflammatory products by human peripheral-blood monocytes was very similarly inhibited by the neutralizing anti-human CD14 mAb 3C10 (not shown).
To further define a functional interaction between Aβ and CD14, we studied the Aβ-induced activation of microglia derived from CD14-deficient or syngenic control mice. CD14-deficient microglia released significantly lower amounts of markers of inflammatory activation (e.g., IL-6, Fig. 2C ) in response to Aβ than corresponding wild-type cells. The same observations were made in peritoneal macrophages derived from these mice (not shown).
It is well known that microglia activated by Aβ kill neurons by release of a large number of inflammatory products (5-7)
. In neurotoxicity studies using the MTT assay, we observed that after stimulation with Aβ, supernatants from CD14-deficient microglia were significantly less toxic for neurons than those from wild-type control microglia (Fig. 2D ). This supports an importance of CD14 in Aβ-induced microglial neurotoxicity.
In a second genetic system that was previously used to establish the key role of CD14 in cellular responses to LPS (22) , CHO-K1 cells were transfected with either a vector carrying CD14 (pCEP4-CD14; CHO CD14+ ) or an empty control vector (CHO
CD14-
). In the EMSA, selectively CD14-transfected CHO cells were activated by Aβ, as shown by the nuclear translocation of NFκB (Fig. 3) . In CHO CD14-cells, translocation of NFκB was absent. Again, the fibrillar conformation of Aβ was a prerequisite for cellular activation (Fig. 3) .
Overexpression of CD14 in APP transgenic mice
We studied expression of CD14 in APP23 mice. In situ hybridization experiments showed a highly positive hybridization signal for CD14 across the cortical and hippocampal formation in 15-month-old APP23 mice (Aβ plaque load: 3.7%; Fig. 4E-H) . In contrast, CD14 mRNA expression was low in brains of aged-matched wild-type mice (Aβ plaque load: 0.0%; Fig. 4C  and D) . Indicating an association with disease progression, CD14 mRNA expression was low in brains of 3-month-old APP23 mice (not shown). Importantly, CD14 mRNA in 15-month-old APP23 mice colocalized with immunoreactivity for iba1, a marker for microglial cells (Fig. 4I and J).
DISCUSSION
We connect the pattern recognition receptor CD14 that is crucial for killing of invading microorganisms (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) with the neurodegenerative disease AD. We observed that the LPS receptor CD14 binds Alzheimer Aβ and mediates Aβ-induced microglial and monocytic activation and toxicity for neurons. The detection of overexpression of CD14 in brains of APP transgenic mice further suggests an importance of this innate immunity receptor in AD pathophysiology.
The CD14 receptor lacks a direct intracellular signal transduction, and the signal of ligation of LPS to CD14 is considered to be transmitted by either Toll-like receptor-2 or Toll-like-receptor-4 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Since these CHO cells used in our experiments lack a functional Toll-like receptor-2, the Toll-like receptor-4 is highly likely the transmit CD14-mediated cellular activation by Aβ.
Our study suggests that in AD, CD14 recognizes the pattern associated with the β-sheet, fibrillar conformation of Aβ, because this receptor interacts with fibrillar but not with nonfibrillar Aβ and because only fibrillar Aβ induced cellular activation. The affinity of fibrillar Aβ to CD14 (K D , 1.06±0.06×10 However, since AD brains contain, in contrast to LPS, very high concentrations of Aβ fibrils for years and decades, it is highly likely that even at this submaximal affinity, this interaction is sufficient to maintain a chronic neuroinflammation.
The presence of CD14 on parenchymal microglia in human neuroinflammation is still unclear. It has been shown that parenchymal microglia after trauma can express CD14 but to a much lower extent compared with perivascular cells (29) . Difficulties to stain CD14 (and also TLR4) with currently available antibodies or an only weak and transient appearance of this receptor at certain stages of cellular activation could be an explanation.
The observation of a CD14-dependent inflammatory response to Aβ fibrils provides the basis for a hypothesis of a structural mimicry between aggregated, highly hydrophobic Alzheimer's Aβ fibrils and biophysically similar pathogen-associated microbial patterns, contributing to chronic neuroinflammation and neurodegeneration in AD. Further receptors have been described to interact with Aβ and mediate cellular activation and neurotoxicity, e.g., scavenger receptors (30, 31) , the receptor for advanced glycation end products (32), the integrin CD11b/CD18 receptor (33) , or the complement factor C1 (34) . Interestingly, at least the scavenger receptors (35) and CD11b/CD18 (36) have been found to contribute to LPS-associated inflammatory responses as "accessory LPS receptors." It might, therefore, be possible that some of these receptors also interact with Aβ through such "structural mimicry mechanism."
Taken together, CD14 may significantly contribute to neuroinflammation in AD, opening the therapeutically relevant perspective that the enormous progress currently being made in the field of innate immunity (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) could be extended to AD research. performed with 50 µg/ml fibrillar (fAβ), nonfibrillar, or scrambled (scrAβ) Aβ, or with 1µg/ml LPS with or without costimulation with IFN-γ (100 U/ml). Release of nitrite is prevented by the anti-CD14 mAb, 4C1. Data are means ± SD. *P < 0.05, compared with effects of isotype control mAbs (ISO); Mann-Whitney U test, with Bonferroni correction. B) Microglial stimulation was performed with 50 µg/ml fibrillar or scrambled Aβ combined with IFN-γ (100 U/ml). The resulting release of IL-6 is prevented by anti-CD14 mAb, 4C1. *P < 0.005, compared with effects of isotype control mAbs (ISO); Mann-Whitney U test. C) After stimulation with fibrillar Aβ (50 µg/ml), microglia from C57Bl6 mice (black bars) readily produce IL-6. Release of this inflammatory marker is strongly reduced in microglia derived from CD14-deficient mice (white bars). *P < 0.05, Mann-Whitney U test. D) Supernatants of Aβ-stimulated microglia are toxic for neurons as detected by MTT assay. Neurotoxicity was strongly reduced when supernatants were derived from CD14-deficient microglia. *P < 0.05, Mann-Whitney U test. 
